Developing a Natural History Model for Duchenne Muscular Dystrophy-Reference-Cited by-同舟云学术

Developing a Natural History Model for Duchenne Muscular Dystrophy

Published:2023-11-29 Issue:1 Volume:8 Page:79-89
ISSN:2509-4262
Container-title:PharmacoEconomics - Open
language:en
Short-container-title:PharmacoEconomics Open

Author:

Broomfield Jonathan^ORCID,Hill M.,Chandler F.,Crowther M. J.,Godfrey J.,Guglieri M.,Hastie J.,Larkindale J.,Mumby-Croft J.,Reuben E.,Woodcock F.,Abrams K. R.,

Funder

Duchenne UK

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Health Policy,Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s41669-023-00450-x.pdf

Reference30 articles.

1. Crisafulli S, Sultana J, Fontana A, Salvo F, Messina S, Trifiro G. Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis. Orphanet J Rare Dis. 2020;15(1):141.

2. San Martín PP, Solis F, Cavada CG. Survival of patients with Duchenne muscular dystrophy. Rev Chil Pediatr. 2018;89(4):477.

3. van den Bergen JC, Ginjaar HB, van Essen AJ, Pangalila R, de Groot IJ, Wijkstra PJ, et al. Forty-five years of duchenne muscular dystrophy in The Netherlands. J Neuromuscul Dis. 2014;1(1):99–109.

4. Wang M, Birnkrant DJ, Super DM, Jacobs IB, Bahler RC. Progressive left ventricular dysfunction and long-term outcomes in patients with Duchenne muscular dystrophy receiving cardiopulmonary therapies. Open Heart. 2018;5(1): e000783.

5. Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A. Duchenne muscular dystrophy. Nat Rev Dis Primers. 2021;7(1):13.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The use of the drug ataluren for the treatment of patients with Duchenne muscular dystrophy in real clinical practice;L.O. Badalyan Neurological Journal;2024-07-31

2. Correction: Developing a Natural History Model for Duchenne Muscular Dystrophy;PharmacoEconomics - Open;2024-07